Please assess the completion status of the following clinical trial:

Trial Title: Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with SLE meeting the 1997 ACR Classification Criteria~* Evidence of positive ANA or anti-dsDNA within one year of screening~* SLEDAI ≥4 or ≥1 BILAG A or B at screening, despite standard of care~Exclusion Criteria:~* Leukopenia (WBC \<2.000/mm3) or lymphopenia (lymphocytes \< 300/mm3)~* AST or ALT \>3 times above normal cut off values~* Acute lupus nephritis defined as class II, IV or V nephritis diagnosed within 6 months or prot/creat \> 1.5 gm/gm due to active lupus or in process of receiving induction therapy for nephritis~* Active CNS lupus affecting mental status~* Pregnancy or breast feeding~* Current requirement for anticoagulation~* Contraindication to aspirin or dipyridamole, including history of recent or severe GI bleeding, hemoglobin \<9 mg/dL, platelet count of \<30,000 /mm3 or unstable platelet count~* Any other medical condition, whether or not related to lupus which, in the opinion of the investigator would render the patient inappropriate or too unstable to complete the study protocol~* Inability or unwillingness to understand and/or sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- extended release dipyridamole/aspirin (Type: EXPERIMENTAL): extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
- aspirin (Type: ACTIVE_COMPARATOR): half a tablet of a 81mg aspirin twice daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).